{"id":26252,"date":"2023-12-15T22:35:07","date_gmt":"2023-12-15T17:05:07","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=26252"},"modified":"2024-09-17T16:57:15","modified_gmt":"2024-09-17T11:27:15","slug":"allo-647-integration-in-lymphodepletion","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/allo-647-integration-in-lymphodepletion","title":{"rendered":"ALLO-647 Integration in Lymphodepletion: Paving the Way for Enduring Responses and Safe CAR T cell Therapy Advancements"},"content":{"rendered":"\n
Date of Abstract presentation<\/td>9th December 2023<\/td><\/tr>
Indications<\/td>Relapsed\/Refractory (r\/r) Large B-Cell and Follicular Lymphomas<\/td><\/tr>
Abstract Number<\/td>2095<\/td><\/tr>
Abstract type<\/td>Poster<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Despite the rising clinical fascination with autologous CAR T-cell therapies for hematologic malignancies and their noteworthy achievements, persistent challenges revolve around logistical issues, manufacturing constraints, variations in quality consistency, and the ongoing struggle to ensure product availability. <\/p>\n\n\n\n

The success of allogeneic CAR T cells hinges on the development of a secure and efficient method to manage the host lymphocyte rejection of these cells, known as allo-rejection. ALLO-501 and ALLO-501A represent allogeneic anti-CD19 CAR T-cell products, utilizing Cellectis technologies’ TALEN<\/strong> gene editing to disrupt both the TCR\u03b1 constant (TRAC) and CD52 genes. Specifically, the disruption of CD52 allows for the use of ALLO-647, facilitating the transient and selective depletion of host lymphocytes. This strategic approach enables ALLO-501 and ALLO-501A to thrive post-infusion, avoiding swift allo-rejection and opening new avenues for effective treatment. The comprehensive safety assessment, encompassing all 87 Phase I patients undergoing treatment for both relapsed\/refractory Large B Cell Lymphoma (LBCL) and follicular lymphoma (FL), reveals that the addition of investigational ALLO-647 to standard lymphodepletion is a safe approach. This strategy creates a favorable window for the expansion and enduring presence of AlloCAR T cells, holding the promise to instigate profound and long-lasting remissions in cases of relapsed and treatment-resistant cancers. Furthermore, no unexpected safety concerns were observed. Neutropenia and anemia were the most common any-grade treatment-emergent adverse events (or TEAEs) and neutropenia, anemia, and thrombocytopenia were the most common Grade 3 or higher TEAEs.<\/p>\n\n\n\n

In November 2023,<\/strong> the company obtained Fast Track Designation (FTD)<\/strong> for the application of ALLO-647<\/strong> in adult patients experiencing relapsed or refractory Large B-cell lymphoma.<\/p>\n\n\n\n

 KOL insights<\/strong><\/strong><\/p>\n\n\n\n

\u201cWe believe in the immense potential of off-the-shelf CAR T products to not only address the limitations of current autologous CAR T cell therapy but to also provide greater access to patients in need. <\/strong>We fully understand the importance of lymphodepletion to achieving optimal outcomes, and ALLO-647 is just the first generation of our innovative approaches to enhancing lymphodepletion to promote expansion of CAR T cells.\u201d \u2013Expert Opinion.<\/strong><\/p>\n\n\n\n

Conclusion<\/strong><\/p>\n\n\n\n

A thorough examination of all participants in the Phase I ALPHA\/ALPHA2 trials reveals that the incorporation of investigational ALLO-647 into standard lymphodepletion not only results in sustained responses but also maintains a safety profile on par with approved autologous CAR T therapies. This comprehensive analysis underscores the potential of ALLO-647 as a promising and safe addition to existing therapeutic approaches in the field.<\/p>\n\n\n\n

Refer to the Related Reports for More In-depth Insights –<\/strong><\/p>\n\n\n\n

\n
\n

Multiple Myeloma Market<\/a><\/strong><\/p>\n\n\n\n

Diffuse Large B-cell Lymphoma Market<\/a><\/strong><\/p>\n\n\n\n

Marginal Zone Lymphoma Market<\/a><\/strong><\/p>\n\n\n\n

Acute Lymphocytic Leukemia (ALL) Market<\/a><\/strong><\/p>\n\n\n\n

Chronic Lymphocytic Leukemia Market<\/a><\/strong><\/p>\n<\/div>\n\n\n\n

\n

Mantle Cell Lymphoma Market<\/a><\/strong><\/p>\n\n\n\n

Hodgkin’s lymphoma Market<\/a><\/strong><\/p>\n\n\n\n

Myelofibrosis Market<\/a><\/strong><\/p>\n\n\n\n

Myelodysplastic Syndrome Market<\/a><\/strong><\/p>\n\n\n\n

Follicular Lymphoma Market<\/a><\/strong><\/p>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Date of Abstract presentation 9th December 2023 Indications Relapsed\/Refractory (r\/r) Large B-Cell and Follicular Lymphomas Abstract Number 2095 Abstract type Poster Despite the rising clinical fascination with autologous CAR T-cell therapies for hematologic malignancies and their noteworthy achievements, persistent challenges revolve around logistical issues, manufacturing constraints, variations in quality consistency, and the ongoing struggle to […]<\/p>\n","protected":false},"author":6,"featured_media":26299,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[41],"tags":[20413,20004,21525,21534,21533,20617,137,841,927,18834,18833,19118],"industry":[17225],"therapeutic_areas":[17233,17228],"class_list":["post-26252","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-snippets","tag-abstracts","tag-american-society-of-hematology","tag-ash-2023","tag-ash-abstracts","tag-ash-annual-meeting-abstracts","tag-b-cell-lymphoma","tag-cancer","tag-cancer-research","tag-cancer-treatment","tag-follicular-lymphoma","tag-follicular-lymphoma-market","tag-large-b-cell-lymphoma","industry-pharmaceutical","therapeutic_areas-hematological-disorders","therapeutic_areas-oncology"],"acf":[],"yoast_head":"\nALLO-647 for Lymphodepletion in the Allogeneic CAR T Setting<\/title>\n<meta name=\"description\" content=\"Safety Experience with ALLO-501\/501A in Patients (Pts) with Relapsed\/Refractory (r\/r) Large B-Cell and Follicular Lymphomas.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/allo-647-integration-in-lymphodepletion\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ALLO-647 for Lymphodepletion in the Allogeneic CAR T Setting\" \/>\n<meta property=\"og:description\" content=\"Safety Experience with ALLO-501\/501A in Patients (Pts) with Relapsed\/Refractory (r\/r) Large B-Cell and Follicular Lymphomas.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/allo-647-integration-in-lymphodepletion\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-12-15T17:05:07+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-17T11:27:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/15223441\/allo-647-integration-in-lymphodepletion.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"ALLO-647 for Lymphodepletion in the Allogeneic CAR T Setting","description":"Safety Experience with ALLO-501\/501A in Patients (Pts) with Relapsed\/Refractory (r\/r) Large B-Cell and Follicular Lymphomas.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/allo-647-integration-in-lymphodepletion","og_locale":"en_US","og_type":"article","og_title":"ALLO-647 for Lymphodepletion in the Allogeneic CAR T Setting","og_description":"Safety Experience with ALLO-501\/501A in Patients (Pts) with Relapsed\/Refractory (r\/r) Large B-Cell and Follicular Lymphomas.","og_url":"https:\/\/www.delveinsight.com\/blog\/allo-647-integration-in-lymphodepletion","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2023-12-15T17:05:07+00:00","article_modified_time":"2024-09-17T11:27:15+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/15223441\/allo-647-integration-in-lymphodepletion.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/allo-647-integration-in-lymphodepletion","url":"https:\/\/www.delveinsight.com\/blog\/allo-647-integration-in-lymphodepletion","name":"ALLO-647 for Lymphodepletion in the Allogeneic CAR T Setting","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/allo-647-integration-in-lymphodepletion#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/allo-647-integration-in-lymphodepletion#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/15223441\/allo-647-integration-in-lymphodepletion.png","datePublished":"2023-12-15T17:05:07+00:00","dateModified":"2024-09-17T11:27:15+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd"},"description":"Safety Experience with ALLO-501\/501A in Patients (Pts) with Relapsed\/Refractory (r\/r) Large B-Cell and Follicular Lymphomas.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/allo-647-integration-in-lymphodepletion"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/allo-647-integration-in-lymphodepletion#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/15223441\/allo-647-integration-in-lymphodepletion.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/15223441\/allo-647-integration-in-lymphodepletion.png","width":1200,"height":800,"caption":"ALLO-647 for Lymphodepletion"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/arawat"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/15223441\/allo-647-integration-in-lymphodepletion-300x200.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Abstracts<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">American Society of Hematology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">ASH 2023<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">ASH Abstracts<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">ASH Annual Meeting Abstracts<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">B-cell Lymphoma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Cancer research<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Cancer Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Follicular Lymphoma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Follicular Lymphoma Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Large B-cell Lymphoma<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Abstracts<\/span>","<span class=\"advgb-post-tax-term\">American Society of Hematology<\/span>","<span class=\"advgb-post-tax-term\">ASH 2023<\/span>","<span class=\"advgb-post-tax-term\">ASH Abstracts<\/span>","<span class=\"advgb-post-tax-term\">ASH Annual Meeting Abstracts<\/span>","<span class=\"advgb-post-tax-term\">B-cell Lymphoma<\/span>","<span class=\"advgb-post-tax-term\">Cancer<\/span>","<span class=\"advgb-post-tax-term\">Cancer research<\/span>","<span class=\"advgb-post-tax-term\">Cancer Treatment<\/span>","<span class=\"advgb-post-tax-term\">Follicular Lymphoma<\/span>","<span class=\"advgb-post-tax-term\">Follicular Lymphoma Market<\/span>","<span class=\"advgb-post-tax-term\">Large B-cell Lymphoma<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 2 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Dec 15, 2023","modified":"Updated on Sep 17, 2024"},"absolute_dates_time":{"created":"Posted on Dec 15, 2023 10:35 pm","modified":"Updated on Sep 17, 2024 4:57 pm"},"featured_img_caption":"ALLO-647 for Lymphodepletion","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/26252","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=26252"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/26252\/revisions"}],"predecessor-version":[{"id":28007,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/26252\/revisions\/28007"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/26299"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=26252"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=26252"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=26252"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=26252"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=26252"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}